Identify the best innovative ideas to improve human health
We care about unmet medical needs and rigorous, highly-translatable data. While data and need drives decisions, intellectual property, competitive analysis, and regulatory paths are also important factors. The inventor is central, and generally external to Celdara.
Collaborate with the inventor to determine the best scientific, preclinical, clinical, and regulatory strategies
Together we define the path to Phase II clinical trial, then work backwards to the present, identifying activities, roles, milestones, key decision points, and often third-party partners who can add additional biotech research and development value to the Program. With a primary focus on significant improvements in human health, a collaborative culture is in our DNA.
Fund the development plan, leveraging non-dilutive sources of capital whenever possible
We love early-stage, change-the-world innovations, even if they appear high-risk. And while we certainly invest our own time and money, non-dilutive development funding fundamentally shifts expected returns, enabling us to work on innovations that others would call “too risky” or “too early” and turn them into assets that have the potential to dramatically improve clinical care.
Develop the asset and/or the business into the clinical stage
This is execution, and this is what we do best. The path is never straight, but our team of outstanding scientists is also a team of outstanding biotechnology risk managers. The inventor is a key member of the team, which is further augmented with external subject matter experts, key opinion leaders, and partners to minimize R&D risk and time-to-IND while maximizing the chance that the asset becomes a valuable clinical candidate. Financial and/or strategic exit partners are engaged as soon as is appropriate.